A new peer-reviewed review published in Current Diabetes Reports examines how GLP-1 and incretin-based medications perform specifically in people who have both obesity and type 2 diabetes — a population with unique challenges that can make weight loss harder and the stakes higher. The findings offer reassurance that these drugs do more than just lower the number on the scale.
What the Review Found
The review, titled "Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes," focuses on the efficacy, safety, and clinical positioning of obesity medications for people managing type 2 diabetes (T2D). According to the published abstract, contemporary incretin receptor agonists — the drug class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — enable clinically meaningful weight loss in people with T2D. Importantly, the benefits extend well beyond the scale: the review highlights improvements in glycemic control and in cardio-renal, hepatic, and functional outcomes.
This matters because people with type 2 diabetes have historically lost less weight on anti-obesity medications than those without diabetes — a phenomenon sometimes called "diabesity disadvantage." The review frames incretin receptor agonists as tools that address both conditions simultaneously rather than forcing clinicians and patients to choose between them.
Why This Is Especially Relevant for People With T2D
Managing obesity alongside type 2 diabetes involves layered complexity. Some older diabetes medications — such as certain insulin formulations and sulfonylureas — can promote weight gain, working against weight-loss efforts. GLP-1 receptor agonists work differently: they help regulate blood sugar while also reducing appetite, slowing gastric emptying, and supporting weight loss. For people with T2D, this dual action is a meaningful clinical advantage. The review specifically notes improvements in cardiorenal and hepatic outcomes, areas where people with diabetes face disproportionately high risk.
Key takeaway: A new review in Current Diabetes Reports confirms that incretin receptor agonists like semaglutide and tirzepatide deliver clinically meaningful weight loss and better blood sugar, heart, kidney, and liver outcomes in people with type 2 diabetes — making them a strong option when both conditions are present.
What This Means for Patients
If you have type 2 diabetes and are considering or already using a GLP-1 medication, this review adds to a growing body of evidence supporting their use. The clinical picture is not just about losing weight — it is about improving the metabolic conditions that drive long-term complications. That said, drug selection, dosing, and monitoring in the setting of T2D should always be individualized, since factors like existing kidney function, cardiovascular history, and current diabetes regimen all influence which medication and dose is most appropriate.
What to Watch Next
The review's publication in Current Diabetes Reports reflects a broader shift in how the medical community is approaching obesity — increasingly treating it as a chronic disease requiring pharmacologic management, not just lifestyle advice. Ongoing and future clinical trials are expected to provide longer-term data on outcomes for people with T2D using these medications. Regulatory agencies continue to evaluate new incretin-based therapies, and treatment guidelines for dual management of obesity and diabetes are likely to keep evolving.
Frequently Asked Questions
As with any medication decision, the best path forward depends on your individual health history, current treatments, and goals. Speak with your prescriber or endocrinologist before starting, stopping, or changing any GLP-1 or diabetes medication.
- Peer-reviewed journal abstract, 'Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes,' Current Diabetes Reports, date not specified in source.